Background: Pro-nerve growth factor must be cleaved to generate mature NGF, which was suggested to be a factor involved in ovarian physiology and pathology. Extracellular proNGF can induce cell death in many tissues. Whether extracellular proNGF exists in the ovary and may play a role in the death of follicular cells or atresia was unknown.
Introduction
The prototype neurotrophin nerve growth factor (NGF) regulates survival of nerve cells upon activation of the TrkA receptor [1] . The precursor of NGF, the larger molecule proNGF, appears to act in an opposite manner, inducing apoptosis upon binding to the p75 neurotrophin receptor (p75 NTR ) -sortilin complex. Clear evidence for p75 NTR -mediated cell death was shown in different cellular systems, including glial cells and neurons [2] and more recently in the heart [3] . Increased levels of proNGF and p75 NTR are typical for the brains of Alzheimer's patients [4] and it was suggested that the levels of proNGF may, in part, be responsible for apoptosis via p75 NTR . Cells can secrete mature NGF and/or the precursor proNGF. In the latter case the levels of either factor in the extracellular space depend on extracellular processing of proNGF. Plasmin [5, 6] , mast cell tryptase [7] and matrix metalloproteinase 7 (MMP7) [5, 8, 9] are well known extracellular enzymes, which are able to process proNGF.
In the female gonad cell proliferation, cell differentiation and cell death occur constantly and must be regulated by systemic and local factors. NGF has also been recognized as such an ovarian factor [10] . It was identified in the ovary of several species, including the human [11] , in which also the pertinent receptors p75 NTR and TrkA were found [12, 13] . The ovarian expression of sortilin, a rather ubiquitous protein, is not studied to our knowledge. Yet, the roles of NGF in human ovarian physiology, including the fate of ovarian follicles or possibly in ovarian pathologies are not fully known. Studies in human granulosa cells (GCs) provided some insights. For example, in human GCs, NGF increased the levels of FSHR mRNA [14] .
NGF pretreatment of human GCs also resulted in higher secretion of oestradiol after exposure to follicle stimulating hormone (FSH) [15] . NGF also enhanced synthesis and secretion of the vascular endothelial growth factor (VEGF) from human GCs in a receptor-dependent manner [16] and has furthermore been implicated in ovarian cancer.
Whether proNGF is present in the (human) ovary, specifically in the extracellular space and in the follicular fluid (FF), was not known, despite of proteomic studies (see, e.g. [17, 18] ). ELISA studies indicated that immunoreactive NGF is produced by isolated human GCs and it was likewise found in human FF, derived from ovulatory follicles [19] [20] [21] [22] . Its levels [20] in FF of polycystic ovarian syndrome (PCOS) -patients were reported to be lower than in women undergoing IVF (in vitro fertilization) for other reasons, or were elevated [23] . Differences in sampling and in selection criteria of PCOS-patients, as well as in IVF-protocols, and ELISA techniques might account for the discrepancies. Yet it is possible that several enzymes present in FF, which can process proNGF and/or NGF, could be at the heart of this difference. For example, MMP9 is present in FF and degrades NGF. Furthermore, higher MMP9 concentrations are reported in PCOS patients [24] . In addition, plasmin, able to cleave proNGF, is produced by GCs [25] , while MMP7 or tryptase, which also cleave proNGF, are not well studied for their presence in FF.
We used IVF-derived human FFs, human and rhesus monkey ovarian sections, and human IVF-derived GCs to study whether in addition to NGF, proNGF could be a factor in the follicle and to explore its function.
Materials and methods
Human GC preparation and culture FF containing GCs was obtained from IVF-patients stimulated according to routine protocols. The Ethics Committee of the LudwigMaximilian-University (LMU) of Munich approved the use of follicular aspirates and GCs for scientific experiments. Written consent of the patients was obtained. The study was carried out according to the guidelines of the 1975 Declaration of Helsinki. All samples and clinical information were anonymized. Aspirates with cells from two to five patients were pooled for the experiments. Cells were separated by centrifugation at 560 × g for 3 min and subsequently washed in serum-free DMEM/Ham's F12 media (PAA, Cölbe, Germany). The supernatant, i.e. FF, was frozen at -20°C until use for Western blot and proNGF ELISA studies. Washed cells were re-suspended in culture media supplemented with penicillin (100 U/mL), streptomycin (100 μg/mL) and 10% (v/v) fetal calf serum (FCS) (all from PAA, Cöbe, Germany) as previously described [26] [27] [28] [29] [30] . Experiments were performed on day 2 or 3 of cell culture, unless otherwise indicated.
Stimulations of the cells were performed in culture media without serum and penicillin/streptomycin. The numbers of replicates are provided for each experiment.
Ovarian samples, immunohistochemistry and immunocytochemistry
Human ovarian sections (from women of the reproductive phase) were derived from the tissue collection of the Institute of Anatomy and Cell Biology (Munich). Monkey ovarian samples from rhesus macaques (Macaca Mulatta, age 5-6 years) were the same as used in previous studies [29] . Collection of tissues was approved by the Oregon National Primate Research Center Institutional Animal Care and Use Committee. Sections (4 μm) were cut from all paraffin-embedded samples and were used for immunohistochemistry, as described [30] . In brief, sections were deparaffinized, subjected to antigen retrieval by heating in citrate buffer (1.8 mM citric acid, 8.2 mM sodium citrate, pH 6.0) at 90°C for 30 min and endogenous peroxidase activity was blocked. Sections were incubated over night with different antisera, followed by a secondary antibody (biotinylated anti rabbit, 1:500, Dianova, Hamburg, Germany) and avidinbiotin complex peroxidase (ABC, Vector Laboratories, Burlingame, CA, USA). The binding was visualized with 3,3′-diaminobenzidin (DAB, Sigma-Aldrich, St. Louis, MO, USA). Incubation with normal non-immune serum instead of the specific antiserum or omission of the primary antiserum served as control as well as preincubation of the antiserum with a specific blocking peptide (Tables 1 and 2 ). The antiserum to proNGF does not cross-react with mature NGF and specifically recognizes a region of the proform. The antiserum to NGF reacted with NGF and proNGF. The specificities of the antisera were tested in a previous study [7] .
Immunocytochemistry on cultured cells (day 1) was performed as described, using anti sortilin antiserum and non-immune serum [7, 31, 32] .
Isolation of RNA and RT-PCR
Total RNA of cultured human GCs (days 1-5 after isolation) was isolated using RNeasy Mini Kit (Quiagen, Hilden, Germany). As previously described [33, 34] 400 ng of total RNA were used for reverse transcription using random hexamer primers and Superscript II (Life Technologies, Karlsruhe, Germany). RT-PCR was performed using different oligonucleotide primers. Controls with H 2 O and RNA instead of cDNA were performed. Amplified PCR products were separated and visualized by ethidium bromide stained agarose gels. The identities of all PCR products were verified by sequencing [30, 35] . For primer sequence information, please see Table 3 .
Western blot
Western blotting was performed as previously described [33] . In brief, human GCs were cultured on 60 mm dishes (Sarstedt, Nürnbrecht, Germany) in DMEM/Ham's F12 media supplemented with 10% (v/v) FCS and 1% (v/v) penicillin/streptomycin. To detect possible small differences in loading and to correct the results accordingly, b-actin served as internal standard. Some antibodies were also used for immunohistochemistry. For control purposes, some antibodies, including proNGF, were pre-incubated with a blocking peptide. This antibody was also used for immunohistochemistry. Western blot bands were visualized with chemiluminescence reagents (PierceThermo Scientific, Waltham, MA, USA). For the list of antibodies and blocking peptides used, please see Tables 1 and 2 . Human GCs were incubated with recombinant proNGF (Cedarlane, Burlington, Canada) and recombinant NGF (Alomone Labs, Jerusalem, Israel) each with 50 ng/mL for 1 h or 24 h in DMEM/Ham's F12 media without FCS, to examine downstream effects on early growth response 1 (EGR1) and choline acetyl-transferase (CHAT) level exerted by the factors. Bands were analyzed with ImageJ Software (National Institute of Health, Bethesda, MD, USA; version 1.45s) and the results normalized to the untreated control.
Cell viability assay
Cell viability was estimated by measuring ATP content, which correlates with cell number and/or viability [34] . For the ATP assay, cells were cultured for 2 days, seeded on white walled 96-well plates (20,000 cells per well) and then exposed to different concentrations of proNGF and NGF for 24 h. Staurosporine (10 μM; Sigma-Aldrich, St. Louis, MO, USA) was used as control. Hundred micro liter of CellTiter-Glo ® reagent (Promega, Mannheim, Germany) were added to each well containing 100 μL of untreated control cells or stimulated cells, avoiding direct light. The contents were mixed for 2 min at 500 rpm on a plate shaker and then incubated for 10 min at room temperature. The fluorescence of the samples was measured in a luminometer (Fluostar, BMG Labtech, Ortenberg, Germany).
Caspase assay
The activities of the effector caspases 3/7 were determined following exposure of human GCs to proNGF and NGF [34, 35] . Cells were cultured for 2 days, seeded on white walled 96-well plates (20, 
Data analysis and statistics
Results obtained were analyzed and depicted using Excel (Microsoft, Redmond, WA, USA) and Prism (GraphPad, La Jolla, CA, USA). Oneway ANOVA-analyses followed by a post hoc test (Newman-Keuls multiple comparison test) were performed. All data are expressed as mean±SEM.
Results
We examined proNGF and NGF by immunohistochemistry in human ovarian large antral follicles ( Figure 1A, B) . We observed that both GCs and theca cells (TCs) were stained. Staining of proNGF disappeared upon pre-adsorption of the antibody with proNGF. Further controls, including non-immune serum, also yielded negative results. To examine the specificities and cross-reactivities of the antibodies used for immmunohistochemistry, they were used for Western blotting. In GC-pellets proNGF was readily detected (Figure 2 was however less abundant than proNGF (Figure 2 , right panel). In the other four out of seven cases immunoreactive NGF was not observed (not shown). Thus, human GCs produce and contain mainly the pro-form of NGF, and its presence in FF suggests that mainly proNGF is secreted into the FF by human GCs.
To explore actions of proNGF and NGF, we used human GCs from culture days 2-3 for functional studies, since qPCR analysis showed low proNGF/NGF mRNA levels at that time of culture (results not shown). Thus actions of exogenous proNGF/NGF should not be confounded by endogenous production. We assessed, whether proNGF and/or NGF can influence cell vitality of human GCs. Different amounts of proNGF and NGF (5 ng/mL-200 ng/mL) were added for 24 h but neither proNGF, nor NGF changed ATP levels ( Figure 3A) . Furthermore, caspase assays did not indicate induction of apoptosis in the proNGF-or NGF-treated cells ( Figure 3B ). Thus, in cultured human GCs proNGF does not cause cell death and NGF does not promote cell proliferation of cultured GCs.
Actions of NGF/proNGF depend on specific receptors. We detected by RT-PCR and Western blotting that human GCs express TrkA/p75 NTR and p75 NTR /sortilin, which may serve as receptors for NGF and proNGF, respectively ( Figure 3C, D, E) . Sortilin was found in cultured GCs but was never seen associated with the cell membrane ( Figure 3E ), and hence proNGF may not be able to activate this cell death pathway. Addition of recombinant NGF (50 ng/mL in serum free media) for 1 h to the GCs significantly increased approximately 2-3-fold the levels of the immediate early gene EGR1, a master transcription factor of the NGF signaling cascade (Figure 4A, B) . Addition of similar amounts of proNGF (50 ng/mL) did not alter EGR1 levels ( Figure 4A, B) . We also detected significantly increased (2.5-fold) levels of CHAT, the enzyme responsible for the production of acetylcholine (ACh), after NGF treatment of GCs (serum free media 50 ng/mL NGF for 24 h; Figure 4C , D), while proNGF (50 ng/mL for 24 h) was not effective (Figure 4C, D) . Thus the actions of NGF in ovarian GCs are similar to the ones in neuronal cells.
Because NGF actions can be witnessed in GCs and NGF can be detected in FF, yet proNGF is mainly produced by GCs, we explored mechanisms that may explain extracellular cleavage of proNGF. We focused on ovarian MMP7, which is an extracellular matrix metalloproteinase, known to process proNGF into its mature form. We detected MMP7 (approx. 25 kDa) in the FF of IVF-patients by Western blotting (n = 5; Figure 5A ), however the levels varied. Using the same antibody, MMP7 was found in human and Rhesus monkey antral follicles by immunohistochemistry. Both species showed positive staining in GCs and TCs of large follicles as well as staining of the FF ( Figure 5B ). Cultured human GCs express MMP7 as shown by RT-PCR and Western blotting ( Figure 5C ), implying that GCs are indeed the source of MMP7 to the FF. This suggests that proNGF is processed by MMP7 in the FF to NGF and that its levels depend on MMP7 levels and activities of this enzyme in FF.
Discussion
To our knowledge, there are no previous reports on proNGF in the ovary and ovarian cells. The NGF precursor was unequivocally found in the present study by using a combination of Western blotting and immunohistochemistry in human samples. They allow the conclusion that proNGF is a GC-derived factor. Our immunohistochemical data (not shown) imply that this is also the case in a nonhuman primate species, the rhesus monkey.
What are the actions of proNGF and NGF in human GCs? Some pieces of information for NGF are available (see introduction). In rat PC12 cells NGF, but not proNGF, increased the transcription factor EGR1 [36] , a result, which we also obtained in human GCs in the present study. EGR1 is regarded as a master transcription factor and is linked to differentiation and mitosis. Furthermore, a previous study showed that NGF increased levels of CHAT in bovine luteal cells [37] . This enzyme is important for the production of ACh from GCs and was also described in the human ovary and GCs [29, [38] [39] [40] . We found that NGF, but not proNGF, elevated the levels of CHAT in human GCs. in cultured GCs, in addition to TrkA. The cellular localization of sortilin appears to be related to its function, as suggested recently [41] . If so, the intracellular localization, rather than membrane-associated localization of sortilin in GCs seen in our study may provide a possible explanation for a lack of proNGF activity in GCs.
The results obtained suggest that proNGF is solely a biologically inactive precursor of NGF in GCs and the generation of active NGF in FF thus depends on extracellular processing in the FF. In the present study we focused on MMP7, known to cleave proNGF [5, 8, 9] . We found that MMP7 is a human and non-human primate GC product and is present in FF in vivo. Thus we assume that it is involved in the cleavage of proNGF in FF, yet other processing enzymes may also be considered. The serine protease tissue plasminogen activator (tPA) catalyzes the conversion of plasminogen to plasmin, which also is an enzyme able to cleave proNGF [5, 6] . It is a product of GCs but its activity appears to be controlled by inhibitors [17, 18, 25] . To our knowledge, there are no studies on the regulation of MMP7 and plasmin in the human ovary. They and precise methods of determination of proNGF and NGF levels will be required to understand the regulation of the ovarian proNGF/NGF system. In summary, the study performed with IVF-derived human FF and GCs reveals that human GCs produce proNGF. Based on cellular studies, we suggest that proNGF in FF is an inactive precursor of NGF, and that biologically active NGF can be generated mainly in the extracellular space, e.g. via the GC-product MMP7. The observed effects of NGF on EGR1 and CHAT, also found in neuronal cells, extend the view that NGF is acting as a trophic molecule for GCs. The apparent lack of proNGF actions in GCs, in face of distinct NGF actions, reveals that the human ovarian proNGF/NGF system is more complex than previously known. Transcriptional/translational control mechanisms may determine levels of these factors in the first place, yet the amounts and the activities of enzymes, which cleave proNGF and NGF in the ovary, may fine-tune the actions of this growth factor system. This work was done in partial fulfillment of the requirements for Dr.rer.nat. projects of SM and JB at the LMU. There are no competing interests.
ACh in the ovary acts as a trophic molecule and regulates ion channel activity in human GCs [40] . In the bovine corpus luteum (CL) [37] it was also reported to exert antiapoptotic actions. Thus NGF appears to be a trophic factor for human GCs.
In cultured human GCs, however, neither exogenous NGF nor proNGF measurably interfered with cell viability/cell number as indicated by unchanged levels of ATP. This may be due to the existing endogenous production of these factors, which may drive the system and may mask effects of exogenous factors. It may also be related to the limited ability of cultured human GCs to proliferate.
Cultured, luteinizing GCs may also differ from follicular GCs especially with regard to susceptibility to cell death and apoptosis and indeed exogenous proNGF did not promote cell death. ATP and caspase assays excluded such actions. Data from our video-imaging studies (results not shown) furthermore supports this conclusion. Actions of proNGF and NGF are initiated upon receptor binding and the receptor molecules linked to proNGF-inducible cell death in brain, namely p75 NTR and sortilin, are present 
